Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor

T. J. Harvey, D. Burdon, L. Steele, N. Ingram, G. D. Hall, P. J. Selby, Richard Geoffrey Vile, P. A. Cooper, S. D. Shnyder, J. D. Chester

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We have assessed the ability of bispecific fusion proteins to improve adenovirus-mediated transfer of therapeutic and marker transgenes. We constructed an expression vector that can be easily modified to synthesize a variety of fusion proteins for retargeting adenoviral gene therapy vectors to cell surface markers, which are differentially expressed between normal and cancer cells. Adenoviral transduction can be improved in a number of tumour cell lines which overexpress EGFR (epidermal growth factor receptor) or uPAR (urokinase-type plasminogen activator receptor), but which have only low levels of endogenous hCAR (human coxsackie B and adenovirus receptor) expression. Up to 40-fold improvement in Β-galactosidase transgene expression was seen using an EGFR retargeting protein, and up to 16-fold using a second fusion protein targeting uPAR. In vitro, our uPAR retargeting fusion protein improved the sensitivity to adenoviral herpes simplex virus thymidine kinase/ganciclovir by an order of magnitude, whereas in vivo, our EGFR retargeting protein is able to significantly delay tumour growth in rodent animal models in a dose-dependent manner. The cassette design of our fusion protein constructs offers a flexible method for the straightforward synthesis of multiple adenoviral retargeting proteins, directed against a variety of tumour-associated antigens, for use in clinical trials.

Original languageEnglish (US)
Pages (from-to)1000-1010
Number of pages11
JournalGene Therapy
Volume17
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Urokinase Plasminogen Activator Receptors
Neoplasm Genes
Epidermal Growth Factor Receptor
Genetic Therapy
Neoplasms
Proteins
Transgenes
Coxsackie and Adenovirus Receptor-Like Membrane Protein
Galactosidases
Ganciclovir
Thymidine Kinase
Neoplasm Antigens
Protein Transport
Simplexvirus
Tumor Cell Line
Adenoviridae
Rodentia
Animal Models
Clinical Trials
Growth

Keywords

  • adenovirus
  • bladder cancer
  • EGFR
  • hCAR
  • retargeting
  • uPAR

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. / Harvey, T. J.; Burdon, D.; Steele, L.; Ingram, N.; Hall, G. D.; Selby, P. J.; Vile, Richard Geoffrey; Cooper, P. A.; Shnyder, S. D.; Chester, J. D.

In: Gene Therapy, Vol. 17, No. 8, 08.2010, p. 1000-1010.

Research output: Contribution to journalArticle

Harvey, TJ, Burdon, D, Steele, L, Ingram, N, Hall, GD, Selby, PJ, Vile, RG, Cooper, PA, Shnyder, SD & Chester, JD 2010, 'Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor', Gene Therapy, vol. 17, no. 8, pp. 1000-1010. https://doi.org/10.1038/gt.2010.45
Harvey, T. J. ; Burdon, D. ; Steele, L. ; Ingram, N. ; Hall, G. D. ; Selby, P. J. ; Vile, Richard Geoffrey ; Cooper, P. A. ; Shnyder, S. D. ; Chester, J. D. / Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. In: Gene Therapy. 2010 ; Vol. 17, No. 8. pp. 1000-1010.
@article{80b1af613e12454bb07ab573a7b9e61e,
title = "Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor",
abstract = "We have assessed the ability of bispecific fusion proteins to improve adenovirus-mediated transfer of therapeutic and marker transgenes. We constructed an expression vector that can be easily modified to synthesize a variety of fusion proteins for retargeting adenoviral gene therapy vectors to cell surface markers, which are differentially expressed between normal and cancer cells. Adenoviral transduction can be improved in a number of tumour cell lines which overexpress EGFR (epidermal growth factor receptor) or uPAR (urokinase-type plasminogen activator receptor), but which have only low levels of endogenous hCAR (human coxsackie B and adenovirus receptor) expression. Up to 40-fold improvement in Β-galactosidase transgene expression was seen using an EGFR retargeting protein, and up to 16-fold using a second fusion protein targeting uPAR. In vitro, our uPAR retargeting fusion protein improved the sensitivity to adenoviral herpes simplex virus thymidine kinase/ganciclovir by an order of magnitude, whereas in vivo, our EGFR retargeting protein is able to significantly delay tumour growth in rodent animal models in a dose-dependent manner. The cassette design of our fusion protein constructs offers a flexible method for the straightforward synthesis of multiple adenoviral retargeting proteins, directed against a variety of tumour-associated antigens, for use in clinical trials.",
keywords = "adenovirus, bladder cancer, EGFR, hCAR, retargeting, uPAR",
author = "Harvey, {T. J.} and D. Burdon and L. Steele and N. Ingram and Hall, {G. D.} and Selby, {P. J.} and Vile, {Richard Geoffrey} and Cooper, {P. A.} and Shnyder, {S. D.} and Chester, {J. D.}",
year = "2010",
month = "8",
doi = "10.1038/gt.2010.45",
language = "English (US)",
volume = "17",
pages = "1000--1010",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor

AU - Harvey, T. J.

AU - Burdon, D.

AU - Steele, L.

AU - Ingram, N.

AU - Hall, G. D.

AU - Selby, P. J.

AU - Vile, Richard Geoffrey

AU - Cooper, P. A.

AU - Shnyder, S. D.

AU - Chester, J. D.

PY - 2010/8

Y1 - 2010/8

N2 - We have assessed the ability of bispecific fusion proteins to improve adenovirus-mediated transfer of therapeutic and marker transgenes. We constructed an expression vector that can be easily modified to synthesize a variety of fusion proteins for retargeting adenoviral gene therapy vectors to cell surface markers, which are differentially expressed between normal and cancer cells. Adenoviral transduction can be improved in a number of tumour cell lines which overexpress EGFR (epidermal growth factor receptor) or uPAR (urokinase-type plasminogen activator receptor), but which have only low levels of endogenous hCAR (human coxsackie B and adenovirus receptor) expression. Up to 40-fold improvement in Β-galactosidase transgene expression was seen using an EGFR retargeting protein, and up to 16-fold using a second fusion protein targeting uPAR. In vitro, our uPAR retargeting fusion protein improved the sensitivity to adenoviral herpes simplex virus thymidine kinase/ganciclovir by an order of magnitude, whereas in vivo, our EGFR retargeting protein is able to significantly delay tumour growth in rodent animal models in a dose-dependent manner. The cassette design of our fusion protein constructs offers a flexible method for the straightforward synthesis of multiple adenoviral retargeting proteins, directed against a variety of tumour-associated antigens, for use in clinical trials.

AB - We have assessed the ability of bispecific fusion proteins to improve adenovirus-mediated transfer of therapeutic and marker transgenes. We constructed an expression vector that can be easily modified to synthesize a variety of fusion proteins for retargeting adenoviral gene therapy vectors to cell surface markers, which are differentially expressed between normal and cancer cells. Adenoviral transduction can be improved in a number of tumour cell lines which overexpress EGFR (epidermal growth factor receptor) or uPAR (urokinase-type plasminogen activator receptor), but which have only low levels of endogenous hCAR (human coxsackie B and adenovirus receptor) expression. Up to 40-fold improvement in Β-galactosidase transgene expression was seen using an EGFR retargeting protein, and up to 16-fold using a second fusion protein targeting uPAR. In vitro, our uPAR retargeting fusion protein improved the sensitivity to adenoviral herpes simplex virus thymidine kinase/ganciclovir by an order of magnitude, whereas in vivo, our EGFR retargeting protein is able to significantly delay tumour growth in rodent animal models in a dose-dependent manner. The cassette design of our fusion protein constructs offers a flexible method for the straightforward synthesis of multiple adenoviral retargeting proteins, directed against a variety of tumour-associated antigens, for use in clinical trials.

KW - adenovirus

KW - bladder cancer

KW - EGFR

KW - hCAR

KW - retargeting

KW - uPAR

UR - http://www.scopus.com/inward/record.url?scp=77955662802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955662802&partnerID=8YFLogxK

U2 - 10.1038/gt.2010.45

DO - 10.1038/gt.2010.45

M3 - Article

C2 - 20410926

AN - SCOPUS:77955662802

VL - 17

SP - 1000

EP - 1010

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 8

ER -